# Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

> **NCT07637734** · PHASE3 · RECRUITING · sponsor: **Verrica Pharmaceuticals Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Common Warts
- Common Warts (Verruca Vulgaris)
- Human Papilloma Virus (HPV)
- Warts

## Interventions

- **COMBINATION_PRODUCT:** VP-102 (US) / TO-208 (Japan)
- **COMBINATION_PRODUCT:** Vehicle (US) / Vehicle (Japan)

## Key facts

- **NCT ID:** NCT07637734
- **Lead sponsor:** Verrica Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-05
- **Final completion:** 2027-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637734, "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*